Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 3
Submit an article Journal homepage
125
Views
5
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study

Giacomo MugnaiDivision of Cardiology, West Vicenza General Hospitals, Arzignano, ItalyCorrespondence[email protected]
,
Carla PaoliniDivision of Cardiology, West Vicenza General Hospitals, Arzignano, Italy
,
Stefano CavedonDivision of Cardiology, West Vicenza General Hospitals, Arzignano, Italy
,
Alessandro MeceneroDivision of Cardiology, West Vicenza General Hospitals, Arzignano, Italy
,
Cosimo PerroneDivision of Cardiology, West Vicenza General Hospitals, Arzignano, Italy
&
Claudio BilatoDivision of Cardiology, West Vicenza General Hospitals, Arzignano, Italy
Pages 264-270 | Received 03 Feb 2021, Accepted 01 May 2021, Published online: 19 May 2021

References

  • Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–883.
  • Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–1583.
  • Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.
  • Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from impiantable cardioverter-defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165–171.
  • Cardiac arrest in Seattle: conventional versus amiodarone drug evaluation (the CASCADE study). Am J Cardiol. 1991;67(7):578–584.
  • Ferreira-Gonzalez I, Dos-Subirá L, Guyatt GH. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J. 2007;28(4):469–477.
  • Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349(9053):667–674.
  • Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–121.
  • Deyell M, Steinberg C, Doucette S, et al. Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. J Cardiovasc Electrophysiol. 2018;29(4):603–608.
  • Rutledge J, Harris F, Amsterdam E. Clinical evaluation of oral mexile- tine therapy in the treatment of ventricular arrhythmias. J Am Coll Cardiol. 1985;6(4):780–784.
  • Campbell NP, Pantridge JF, Adgey AA. Long-term oral antiarrhythmic therapy with mexiletine. Br Heart J. 1978;40(7):796–801.
  • Campbell RW. Mexiletine. N Engl J Med. 1987;316(1):29–34.
  • Manolis AS, Deering TF, Cameron J, et al. Mexiletine: pharmacology and therapeutic use. Clin Cardiol. 1990;13(5):349–359.
  • Gottlieb SS, Weinberg M. Comparative hemodynamic effects of mexiletine and quinidine in patients with severe left ventricular dysfunction. Am Heart J. 1991;122(5):1368–1374.
  • Gao D, Herendael HV, Alshengeiti L, et al. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J Cardiovasc Pharmacol. 2013;62(2):199–204.
  • Sobiech M, Lewandowski M, Zając D, et al. Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks. Kardiol Pol. 2017;75(10):1027–1032.
  • Viskin S, Chorin E, Viskin D, et al. Quinidine-responsive polymorphic ventricular tachycardia in patients with coronary heart disease. Circulation. 2019;139(20):2304–2314.
  • Fedida D, Orth PMR, Hesketh JC, et al. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S71–S78.
  • Williams EM. Mexiletine in isolated tissue models. Postgrad Med J. 1977;53(Suppl 1):30–34.
  • Duff HJ, Sheldon RS, Cannon NJ. Tetrodotoxin: sodium channel specific anti-arrhythmic activity. Cardiovasc Res. 1988;22(11):800–807.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.